Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Bio-Rad Laboratories (BIO) Stock Price & Analysis
835 Followers
BIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$261.59 - $431.79
Previous Close$263.97
Volume163.34K
Average Volume (3M)248.18K
Market Cap
$7.65B
Enterprise Value$7.30B
Total Cash (Recent Filing)$1.65B
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Jul 25, 2024EPS Estimate
$2.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.37
Shares Outstanding28,524,797
10 Day Avg. Volume366,879
30 Day Avg. Volume248,181
Standard Deviation0.10
R-Squared0.24
Alpha-0.00652
Financial Highlights & Ratios
Price to Book (P/B)1.03
Price to Sales (P/S)11.05
Price to Cash Flow (P/CF)25.30
P/FCF Ratio42.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.80
Enterprise Value/Gross Profit5.12
Enterprise Value/Ebitda-22.80
Forecast
1Y Price Target
$350.50Price Target Upside30.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bio-Rad Laboratories News
PremiumMarket News
SPY ETF Update, 5/9/2024 
PremiumMarket News
SPY ETF Update, 5/7/2024 
PremiumPre-Earnings
Is BIO a Buy, Before Earnings?Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $261.59 and its highest was $431.79 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Currently, no data Available
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is Jul 25, 2024 which is in 23 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on May 07, 2024. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.146 by $0.144.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is $2.02.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 23,445,692 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.29 in its last earnings report, beating expectations of $2.146. Following the earnings report the stock price went down -4.162%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Among the largest hedge funds holding Bio-Rad Laboratories’s share is Southeastern Asset Management Inc. It holds Bio-Rad Laboratories’s shares valued at 119M.
---
Bio-Rad Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$350.50 (30.94% Upside)
$350.50 (30.94% Upside)
Blogger Sentiment
Bullish
BIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 16.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $252.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.37%
12-Months-Change
Fundamentals
Return on Equity
-3.43%
Trailing 12-Months
Asset Growth
-7.74%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
---
BIO Earnings Call
Q1 2024
0:00 / 0:00
---
BIO Net sales Breakdown
55.75% Clinical Diagnostics
44.11% Life Science
0.13% Other
---
BIO Stock 12 Month Forecast
Average Price Target
$350.50
▲(30.94% Upside)
Technical Analysis
Best Analysts Covering BIO
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+5.89%
reiterated a buy rating 2 months ago
Copying Dan Leonard's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +5.89% per trade.
---